Search Results - "Nishimiya, Noriko"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease by Nishimiya, Noriko, Tajima, Kazuki, Imajo, Kento, Kameda, Akiko, Yoshida, Eiko, Togashi, Yu, Aoki, Kazutaka, Inoue, Tomio, Nakajima, Atsushi, Utsunomiya, Daisuke, Terauchi, Yasuo

    Published in Internal Medicine (01-11-2021)
    “…Objective We assessed the effect of canagliflozin, an sodium-glucose co-transporter type-2 inhibitor, on hepatic steatosis using three imaging modalities:…”
    Get full text
    Journal Article
  2. 2

    Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease by Nishimiya, Noriko, Tajima, Kazuki, Imajo, Kento, Kameda, Akiko, Yoshida, Eiko, Togashi, Yu, Aoki, Kazutaka, Inoue, Tomio, Nakajima, Atsushi, Utsunomiya, Daisuke, Terauchi, Yasuo

    Published in Internal Medicine (2021)
    “…Objective We assessed the effect of canagliflozin, an SGLT2 inhibitor, on hepatic steatosis using three imaging modalities: magnetic resonance imaging (MRI),…”
    Get full text
    Journal Article
  3. 3

    Quantitative analysis of vascular signs on early postmortem multi-detector computed tomography by Torimoto, Izumi, Takebayashi, Shigeo, Sekikawa, Zenjiro, Nishimiya, Noriko, Morimura, Naoto, Inoue, Tomio

    Published in SpringerPlus (01-04-2014)
    “…Purpose To clarify the postmortem multi-detector computed tomography (MDCT) vascular signs that occur shortly after death. Materials and methods The vascular…”
    Get full text
    Journal Article
  4. 4